LuminusMicro Appoints New COO, Earns NIH Recognition, and Prepares for ENT Market Launch

Q3 2023

Luminus Holdings is proud to announce the addition of several new members to our management team and advisory board, bringing extensive experience in commercialization, from product inception to global expansion. Among them is Paul Maccini, a seasoned senior executive with over three decades of leadership in Biotech and Med-Devices. Paul has successfully propelled multiple companies to surpass $1 billion USD in revenue in over 40 countries, by balancing market vision, operational efficiency, compliance, and world class service. Under Mr. Maccini, all Luminus departments will scale to meet demand, including production capacity, optimized supply chains, enhanced distribution channels, advanced product education and training.

LUMINUSMICRO RECOGNIZED BY US NIH AS FEATURE TECHNOLOGY

We are thrilled to announce that Precision Surgical Interventions (PSI), a division of the US National Institutes of Health (NIH) Cancer Research department, has selected LuminusMicro devices as a feature technology for presentation at their upcoming collaborative conference on September 7 in Chicago. This recognition underscores PSI’s commitment to accelerating the adoption of new diagnostic and therapeutic standards of care. Notably, this marks the second occasion that the NIH has acknowledged LuminusMicro as a breakthrough technology, citing previous collaboration with the Heart & Lung division on procedures that offer innovative access within this anatomy.

RECENT ACQUISITION IN THE ENT MARKET

In a significant development within the ENT market landscape, Medtronic has recently completed the acquisition of Intersect, an ENT pharmaceutical stent-implant company, for $1.1 billion. This acquisition holds profound relevance for Luminus as the optimal placement of their products in ENT anatomy necessitates direct endoscopic visualization. This capability is currently absent in doctors office settings using conventional devices. Until the launch of ENTnano, no device can offer this critical functionality without resorting to traumatic surgical procedures under extensive anesthesia.